68Ga-DOTA.SA.FAPi PET 在 177Lu 微球选择性动脉内放射性核素治疗不可切除的肝细胞癌后的反应评估中的应用。
68Ga-DOTA.SA.FAPi PET in Response Assessment After 177Lu-Microspheres Selective Intra-arterial Radionuclide Therapy for Unresectable Hepatocellular Carcinoma.
发表日期：2024 Aug 01
作者：
Sejal Chopra, Yamini Mathur, Frank Roesch, Euy Sung Moon, Harmandeep Singh, Naveen Kalra, Ajay Duseja, Bhagwant Rai Mittal, Jaya Shukla
来源：
CLINICAL NUCLEAR MEDICINE
摘要：
我们报道了一名患有复发性肝细胞癌的 48 岁男性病例，他接受了 FDG PET 重新分期，并在 III 段（SUVmax，5.7）中发现了轻度示踪剂增强的动脉增强病变。由于 FDG 摄取量低，患者计划接受 68Ga-SA.FAPi PET，这表明病灶中示踪剂亲和力较高（SUVmax，24.4）。随后，患者在第 III 段接受 177Lu 微球 SIRT (2.2 GBq)。治疗后 3 个月和 6 个月的 SA.FAPi PET 显示示踪剂摄取和治疗病灶大小出现间歇性下降。该案例凸显了 SA.FAPi PET 在 177Lu-SIRT 患者选择和后续反应评估中的前景广阔的作用。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。
We report a case of a 48-year-old man with recurrent hepatocellular carcinoma, who underwent FDG PET for restaging and demonstrated mildly tracer-avid arterial enhancing lesion in segment III (SUVmax, 5.7). Owing to low FDG uptake, patient was planned for 68Ga-SA.FAPi PET, which demonstrated higher tracer avidity in the lesion (SUVmax, 24.4). Subsequently, patient underwent 177Lu-microsphere SIRT (2.2 GBq) in segment III. The 3- and 6-month posttherapy SA.FAPi PET demonstrated an interval decrease in tracer uptake and size of treated lesion. This case highlighted the promising role of SA.FAPi PET in patient selection for 177Lu-SIRT and subsequent response assessment.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.